S
Sagar U. Nigwekar
Researcher at Harvard University
Publications - 138
Citations - 5068
Sagar U. Nigwekar is an academic researcher from Harvard University. The author has contributed to research in topics: Calciphylaxis & Kidney disease. The author has an hindex of 32, co-authored 121 publications receiving 3987 citations. Previous affiliations of Sagar U. Nigwekar include Rochester General Health System & University of Rochester.
Papers
More filters
Journal ArticleDOI
Calciphylaxis from Nonuremic Causes: A Systematic Review
TL;DR: Calciphylaxis should be considered while evaluating skin lesions in patients with predisposing conditions even in the absence of end-stage kidney disease and renal transplantation, suggesting that heterogeneous mechanisms may contribute to its pathogenesis.
Journal ArticleDOI
Calciphylaxis: risk factors, diagnosis, and treatment.
Sagar U. Nigwekar,Daniela Kroshinsky,Rosalynn M. Nazarian,Jeremy Goverman,Rajeev Malhotra,Vicki A. Jackson,Mihir Kamdar,David J.R. Steele,Ravi Thadhani +8 more
TL;DR: High-quality evidence for the evaluation and management of calciphylaxis is lacking at this time due to its rare incidence and poorly understood pathogenesis and the relative paucity of collaborative research efforts, so a summary of recommendations developed by a multidisciplinary team for patients with calciphyllaxis is provided.
Journal ArticleDOI
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
Tamara Isakova,Thomas L. Nickolas,Michelle R. Denburg,Sri G. Yarlagadda,Daniel E. Weiner,Orlando M. Gutiérrez,Vinod Bansal,Sylvia E. Rosas,Sagar U. Nigwekar,Jerry Yee,Holly Kramer +10 more
TL;DR: This commentary presents the views of the KDOQI CKD-MBD work group, which agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives.
Journal ArticleDOI
The treatment of hyponatremia.
TL;DR: Therapy should keep the patient safe from serious complications of hyponatremia while staying well clear of correction rates that risk iatrogenic injury, including the newly available vasopressin antagonists.
Journal ArticleDOI
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
TL;DR: Aldosterone antagonists reduce proteinuria in CKD patients already on ACEis and ARBs but increase the risk of hyperkalemia.